Dr Kate Perry, Group Behavioral Science Director, showcased a poster at the 29th annual ESPACOMP conference in Málaga, Spain, 2025.
We featured findings from our 2024 global oncology patient research, applying our behavioral science approach to understanding and improving adherence in self-administered cancer treatment.
Through a cross-sectional survey of adults with cancer, we identified four key behavioral drivers of intentional nonadherence:
-
sensitivity to medicines
-
testing treatment
-
inconvenience
-
resisting illness and medication
Our analysis demonstrated that these factors are highly prevalent among nonadherent patients, highlighting the need for tailored, person-centered interventions to optimize health-related behaviors.
We proposed Acceptance and Commitment Therapy (ACT) as a promising and flexible framework that has evidence of effectiveness applied to cancer patients and caregivers, with processes designed to address openness to treatment doubts, mindful engagement with routines, and values-based action despite illness.
The findings emphasize the importance of understanding the psychological factors and individual motivations that support medication adherence. Conference attendees recognized the value of our work in advancing personalized strategies for oncology care, underscoring the potential impact of behavioral science in improving patient outcomes in oncology.
To discuss the research in more detail and receive a copy of our Treatment Motivators analysis, contact kate.perry@atlantishealth.com